Methods for treating neurodegenerative disorders using aspartyl protease inhibitors
View Patent ↗The present invention relates to () non-peptide aspartyl protease inhibitors; (ii) methods for modulating the processing of an amyloid precursor protein (APP); (iii) methods for modulating the processing of a tau protein (τ-protein); and (iv) methods for treating neurodegenerative diseases. For instance, in one embodiment, the present invention provides a method for modulating the processing of an amyloid precursor protein (APP), the method comprising contacting a composition containing the APP with an aspartyl protease inhibitor having the formula: wherein: R 1, R 2 and R 3 are members independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, aryloxyalkyl, substituted aryloxyalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heterocycles, substituted heterocycles, heterocyclicalkyl and substituted heterocyclicalkyl; and R 5 and R 6 are independently selected from the group consisting of hydrogen, halogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, aryloxyalkyl and substituted aryloxyalkyl; or R 5 and R 6 and the carbons to which they are bound join to form an optionally substituted carbocyclic or heterocyclic fused ring system having a total of 9- or 10-ring atoms within the fused ring system.
1. A method for modulating the processing of an amyloid precursor protein (APP), said method comprising contacting a composition containing said APP with an aspartyl protease inhibitor having the general formula:
wherein:
R 1 , R 2 and R 3 are members independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, aryloxyalkyl, substituted aryloxyalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heterocycles, substituted heterocycles, heterocyclicalkyl and substituted heterocyclicalkyl; and
R 5 and R 6 are independently selected from the group consisting of hydrogen, halogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, aryloxyalkyl and substituted aryloxyalkyl; or R 5 and R 6 and the carbons to which they are bound join to form an optionally substituted carbocyclic or heterocyclic fused ring system having a total of 9- or 10-ring atoms within said fused ring system.
2. The method according to claim 1 , wherein:
R 1 is a member selected from the group consisting of substituted alkylaryl, substituted aryl, substituted alkyl and substituted heterocyclic groups.
3. The method according to claim 2 , wherein:
R 1 is a member selected from the group consisting of:
4. The method according to claim 1 , wherein:
R2 is a member selected from the group consisting of substituted alkyl, heterocyclic and substituted heterocyclic groups.
5. The method according to claim 4 , wherein R 2 is a member selected from the group consisting of:
6. The method according to claim 1 , wherein:
R 3 is a member selected from the group consisting of substituted alkyl and substituted aryl groups.
7. The method according to claim 6 , wherein R 3 is a member selected from the group consisting of:
8. The method according to claim 1 , wherein R 5 and R 6 and the carbons to which they are bound form an optionally substituted napthalene ring.
9. The method according to claim 1 , wherein R 5 and R 6 are both hydrogen.
10. The method in accordance with claim 1 , wherein R 5 is hydrogen and R 6 is meta or para to R 5 and is a member selected from the group consisting of halogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, aryloxyalkyl and substituted aryloxyalkyl.
11. The method according to claim 1 , wherein said aspartyl protease inhibitor is a member selected from the group consisting of:
12. The method according to claim 1 , wherein said aspartyl protease inhibitor is a member selected from the group consisting of:
13. The method in accordance with claim 1 , wherein said aspartyl protease inhibitor is a member selected from the group consisting of
CEL5-A having the following structure:
having the following structure: CEL5-G:
; and
EA 1 having the following structure:
14. The method in accordance with claim 1 , where in said composition is a body fluid.
15. The method in accordance with claim 13 , 14 , wherein said body fluid is cerebral spinal fluid.
16. The method in accordance with claim 1 , whereby formation of amyloidogenic Aβ peptides (Aβ) is decreased compared to the amount formed in the absence of said aspartyl protease inhibitor.
17. The method in accordance with claim 1 , whereby formation of α-sAPP is increased compared to the amount formed in the absence of said aspartyl protease inhibitor.
18. The method in accordance with claim 1 , wherein the modulation is effected by modulating the activity of cathepsin D.
19. A method for modulating the processing of a tau-protein (τ-protein), said method comprising contacting a composition containing said τ-protein with an aspartyl protease inhibitor having the general formula:
wherein:
R 1 , R 2 and R 3 are members independently selected from the group consisting of alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, aryloxyalkyl, substituted aryloxyalkyl, heteroaryl, substituted heteroaryl, heteroarylalkyl, substituted heteroarylalkyl, heterocycles, substituted heterocycles, heterocyclicalkyl and substituted heterocyclicalkyl; and
R 5 and R 6 are independently selected from the group consisting of hydrogen, halogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, aryloxyalkyl and substituted aryloxyalkyl; or R 5 and R 6 and the carbons to which they are bound join to form an optionally substituted carbocyclic or heterocyclic fused ring system having a total of 9- or 10-ring atoms within said fused ring system.
20. The method according to claim 19 , wherein:
R 1 is a member selected from the group consisting of substituted alkylaryl, substituted aryl, substituted alkyl and substituted heterocyclic groups.
21. The method according to claim 20 , wherein:
R 1 is a member selected from the group consisting of:
22. The method according to claim 19 , wherein:
R 2 is a member selected from the group consisting of substituted alkyl, heterocyclic and substituted heterocyclic groups.
23. The method according to claim 22 , wherein R 2 is a member selected from the group consisting of:
24. The method according to claim 19 , wherein:
R 3 is a member selected from the group consisting of substituted alkyl and substituted aryl groups.
25. The method according to claim 24 , wherein R 3 is a member selected from the group consisting of:
26. The method according to claim 19 , wherein R 5 and R 6 and the carbons to which they are bound form an optionally substituted napthalene ring.
27. The method according to claim 19 , wherein R 5 and R 6 are both hydrogen.
28. The method in accordance with claim 19 , wherein R 5 is hydrogen and R 6 is meta or para to R 5 and is a member selected from the group consisting of halogen, alkyl, substituted alkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, aryloxyalkyl and substituted aryloxyalkyl.
29. The method according to claim 19 , wherein said aspartyl protease inhibitor is a member selected from the group consisting of:
30. The method according to claim 19 , wherein said aspartyl protease inhibitor is a member selected from the group consisting of:
31. The method in accordance with claim 19 , wherein said aspartyl protease inhibitor is a member selected from the group consisting of
CEL5-A having the following structure:
CEL5G having the following structure:
; and
EA 1 having the following structure:
32. The method in accordance with claim 19 , wherein said composition is a body fluid.
33. The method in accordance with claim 32 , wherein said body fluid is cerebral spinal fluid.
34. The method in accordance with claim 19 , whereby formation of τ-fragments is decreased compared to the amount formed in the absence of said aspartyl protease inhibitor.
35. The method in accordance with claim 19 , wherein the modulation is effected by modulating the activity of cathepsin D.